Candida Real-time PCR panel for the rapid identification/detection of Candida albicans, C. glabrata, C. tropicalis, C. krusei, C. parapsilosis & C. auris. Allowing for appropriate anti-fungal therapy or modification of therapy with patients afflicted with one of the targeted organisms - many which have known drug resistance.
The incidence of candidemia has been rising worldwide over the last decades, amounting to be the fourth highest bloodstream infection in hospitalized patients. This is believed to be due to the increase in predisposing factors, such as immunosuppression, critical illness, advanced age, the use of broad-spectrum antibiotics, as well as indwelling venous catheters1. Currently, clinicians utilize culture methods to ID Candida species, resulting in long turnaround times and sometimes misdiagnosis. This Candida real-time PCR panel is a diagnostic qPCR assay detecting six clinically relevant Candida species to allow clinicians to rapidly treat patients identified with one or more of the six drug resistant Candida species in one sample type.
Candidiasis is a multifaceted disease caused by the yeast Candida. Candida is a normal colonizer of the human body, living in places such as the mouth, throat, intestinal tract, and vulva-vaginal area. When Candidiasis becomes invasive it is a serious infection, infecting the blood stream or internal organs. Often times people who develop Candidiasis have underlying medical conditions which makes it difficult for clinicians to diagnose without supplementary testing.
As an entity, candidemia is one of the most common healthcare-associated bloodstream infections in US hospitals, typically ranking as the third or fourth most common cause of healthcare–associated bloodstream infection. The continued reliance on blood cultures, which are notoriously insensitive as markers of disease, remains a significant obstacle to early intervention for this condition. The development of reliable nonculture assays is critical to providing the opportunity for earlier intervention and more targeted antifungal therapy among large numbers of patients in whom traditional blood cultures are insensitive or provide untimely results. Each Candida species presents its own unique characteristics with respect to tissue tropism, propensity to cause invasive disease, virulence, and antifungal susceptibility. Mucosal Candida infections—especially those involving the oropharynx, esophagus, and vagina—are not considered to be classically invasive disease.
Candidemia is one of the most common bloodstream infections in the U.S., with an incidence rate of approximately 9 per 100,000 people or roughly 25,000 each year. Due to the symptomology similarities to bacterial or viral infections clinicians will either obtain a blood sample or a sample from a suspected infection site for specialized laboratory testing (serological or culturing). The Candida yeast generally grows easily on standard culture media, but it can still take several days for proper identification to the species level. The CDC has reported that several “automated” identification systems for yeast misidentify C. auris. Polymerase Chain Reaction technology does not have this limitation.
Extraction of genomic acid from whole blood specimen followed by PCR amplification of targets using real-time PCR methods. An internal control is added to ensure that extraction was performed correctly, and that the PCR reaction was not inhibited.
No cross reactivity was observed with off target bacterial and fungal blood borne pathogens.
For whole blood sample types: Same day (within 24 hours of receipt of specimen)
|87481 x 6
2 mL (0.5mL min volume)
Qualitative Results: Detected/Not Detected
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with the patient’s name and collection date. A Eurofins Viracor test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Eurofins Viracor, 18000 W 99th St. Ste, #10, Lenexa, KS 66219
A negative test result cannot rule out the diagnosis of candidiasis.
Causes for Rejection
Specimens beyond their acceptable length of time from collection as listed in the specimen handling.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Eurofins Viracor's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
- El Zakhem, A.; El Eid, R.; Istambouli, R.; Tamim, H.; Kanj, S.S. The Utility of EQUAL Candida Score in Predicting Mortality in Patients with Candidemia. J. Fungi 2022, 8, 238. https://doi.org/10.3390/jof8030238
- Emerging fungal pathogen: Candida auris, Tyler M. Barrett1 and Clement K. M. Tsui
- So Many Diagnostic Tests, So Little Time: Review and Preview of Candida auris Testing in Clinical and Public Health Laboratories, Emily K. Dennis, Sudha Chaturvedi, and Vishnu Chaturved
- Candida auris outbreak involving liver transplant recipients in a surgical intensive care unit, Nicole M. Theodoropoulos
- Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris, Andrea Cortegiani
- Donor-Derived Transmission of Candida auris During Lung Transplantation, Marwan M. Azar
- Forsberg K, Woodworth K, Walters M, et al. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. Med Mycol 2019; 57:1–12.
- Antibiotic Resistant Threats in The United States 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 14 August 2022.
- Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the First Seven Reported Cases of 5 Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016. Am J Transpl 2017; 17:296–299.
- Peter G. Pappas, Carol A. Kauffman, David R. Andes, Cornelius J. Clancy, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
- Healthcare Cost and Utilization Project (HCUP)
- National Inpatient Sample (NIS)
- National Ambulatory Medical are Survey (NAMCS)
- National Hospital Ambulatory Medical Care Survey (NHAMCS)